This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Bovine testicular hyaluronidase
Description: Hydase is a preparation of purified bovine testicular hyaluronidase. Its exact chemical structure is unknown, but the amino acid sequence for the primary structure of the enzyme has been ascertained based upon the sequence of purified peptides.
Hyaluronidase is being investigated for its ability to break down hyaluronic acid (HA), the space-filling gel-like substance that is a major component of tissues throughout the body. Hyaluronidase, injected in the skin or in the muscle, can temporarily digest the HA gel to enhance the penetration and diffusion of other injected drugs or fluids. When no spreading agent is present, subcutaneously injected materials tend to spread very slowly.
Deal Structure: In January 2007, Akorn entered an Exclusive Supply Agreement with PrimaPharm to supply Hydase. Hydase will be manufactured by PrimaPharm, who owns the NDA, and Akorn received exclusive marketing and distribution rights in the U.S. and Puerto Rico.
Partners: Primapharm, Inc.
Pink Sheet Approval In Brief
Pink Sheet Biosimilar By Name and Biosimilar By Nature
Additional information available to subscribers only: